Literature DB >> 1493842

Prevalence of drug-treated diabetes mellitus in Belgium. Results of a study with the collaboration of a network of pharmacies.

D Walckiers1, J Van der Veken, L Papoz, A Stroobant.   

Abstract

Within the framework of a European concerted action on diabetes mellitus (EURODIAB SubArea C), an epidemiological study was established in Belgium in 1990 in order to estimate the prevalence of drug-treated diabetes mellitus. An assessment was made of the sales of insulin and oral antidiabetic drugs and the average daily dose used. A sample of people with diabetes, clients of 107 pharmacies, provided the data to establish average daily doses. Those pharmacies, spread over the 9 provinces of the country, represent 2% of all private pharmacies in Belgium. Over a 2 month period each pharmacist presented a questionnaire to each client receiving an antidiabetic drug. In 1990, 164 per 10,000 inhabitants were treated with antidiabetic drugs, which means that there were approximately 163,000 drug-treated diabetics in Belgium. At the time of the survey 65% of the diabetics in the sample were 60 years or older. Overall, 38% of drug-treated diabetics took insulin, and 30% of them took only human insulin. Treatment type varied by the province where the pharmacy was located. The provinces of Hainaut and Luxembourg-Namur had a higher percentage of diabetics on oral treatment. This is the first description in Belgium of the prevalence of drug-treated diabetes and of the pattern of prescribing of these drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493842     DOI: 10.1007/bf02284959

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  European Community Concerted Action Programme in Diabetes (EURODIAB)

Authors:  J H Fuller
Journal:  Diabet Med       Date:  1989-04       Impact factor: 4.359

2.  [Diabetes in the Belgian province of Luxembourg: frequency, importance of the oral glucose tolerance test and a modestly increased fasting blood glucose].

Authors:  D Hortulanus-Beck; P J Lefebvre; M F Jeanjean
Journal:  Diabete Metab       Date:  1990 Jul-Aug

3.  [Prevalence of diabetes mellitus in the province of Guadalajara].

Authors:  A L Calle Pascual; V Gómez Ballesteros; E León Carralafuente
Journal:  Med Clin (Barc)       Date:  1988-01-09       Impact factor: 1.725

4.  Drug sales data and prevalence of diabetes in France.

Authors:  A Fontbonne; L Papoz; E Eschwege
Journal:  Rev Epidemiol Sante Publique       Date:  1986       Impact factor: 1.019

5.  Pattern of treatment among diabetic patients in France.

Authors:  L Papoz; F Vauzelle; P Vexiau; G Cathelineau
Journal:  Diabetes Care       Date:  1988 Jul-Aug       Impact factor: 19.112

6.  Utilization of antidiabetic drugs in the Island of Gotland, Sweden: agreement between wholesale figures and prescription data.

Authors:  U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

7.  The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden.

Authors:  U Bergman; P Elmes; M Halse; T Halvorsen; H Hood; P K Lunde; F Sjöqvist; O L Wade; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

  7 in total
  1 in total

1.  Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices.

Authors:  J Wens; V Van Casteren; E Vermeire; P Van Royen; L Pas; J Denekens
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.